Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
about
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsAdverse events of interferon beta-1a: a prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practiceThe interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alonRelapsing-remitting multiple sclerosis: patterns of response to disease-modifying therapies and associated factors: a national survey.Predictors of disability worsening in clinically isolated syndrome.Interferon-beta 1b in the treatment of multiple sclerosis.Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis?Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies.Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey.Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.Pharmacotherapy of multiple sclerosis: the PROOF trial.Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis.Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteriaThe inclusion of real world evidence in clinical development planning
P2860
Q26752859-DCC9C7CD-DCA0-4457-85BA-415049E9EB86Q28743480-2134B3E0-F6CA-4FE3-BA34-48B6A095E0D8Q35276609-0A8D531A-A04C-4D41-BC5B-1D6ABFDFC0CBQ35280670-79E06918-D1C0-415F-B6C2-3CCF2C833E09Q35619185-AC3032A9-E179-4739-9772-80178FF5F911Q36327113-718A2908-C4E2-4ED5-B2F4-320A3DC0574CQ36359388-5DA5B201-3E78-461A-AC51-0FDE4E8DA167Q37706612-83795DCF-8D3C-4F0E-956B-FE79CA34D893Q37976344-4B9A5B48-A564-4D57-ADBE-9292C9AE9456Q38050313-617C4BD8-E3D8-47C3-86B7-B232F619DD5DQ39025672-3B2C28F0-9845-4655-BE05-3BFD9DE9BD2DQ39061969-E48002FF-4844-49FE-A552-E0489D7DBD8FQ42687809-0CF54B2B-0E87-4944-8871-71B8BD61D15DQ43609601-CA35FC3C-FC5A-4173-91CA-4251F0C96F76Q47639943-5A68AEA1-1FC6-44E6-BADE-85FFCF3AEC25Q47743703-B19A6A3F-B298-47BD-9CC3-3EBABC3141A3Q50787818-DFDCC1B0-60D5-446D-B6B6-A202B83B4280Q58452069-9745E6B8-B6B9-4664-A722-D59D19688A43Q58694932-926C22C9-44E1-4E59-AEFD-81D18EA755A1
P2860
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Interferon beta in relapsing-r ...... eting study in southern Italy.
@en
Interferon beta in relapsing-r ...... eting study in southern Italy.
@nl
type
label
Interferon beta in relapsing-r ...... eting study in southern Italy.
@en
Interferon beta in relapsing-r ...... eting study in southern Italy.
@nl
prefLabel
Interferon beta in relapsing-r ...... eting study in southern Italy.
@en
Interferon beta in relapsing-r ...... eting study in southern Italy.
@nl
P2093
P2860
P50
P921
P1476
Interferon beta in relapsing-r ...... eting study in southern Italy.
@en
P2093
Aurora Fuiani
Carlo Avolio
Damiano Paolicelli
Fabrizio Giuliani
Francesca De Robertis
Giovanni Bosco Zimatore
Southern Italy MS Group
P2860
P304
P356
10.1191/1352458503MS948OA
P577
2003-10-01T00:00:00Z